By Daniella Parra
A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma patients, outperforming traditional clinical markers, SkylineDx said.
Risk stratification by SKY92 showed significant differences in survival end points, with SKY92 standard-risk patients having a 3-year PFS and OS of 66% and 92% while SKY92 high-risk patients have a 3-year PFS and OS of 39% and 76% respectively, they said.
“This publication confirms years of scientific work and collaboration,” said Jvalini Dwarkasing, PhD, Chief Scientific Officer at SkylineDx. “The SKY92 signature brings molecular precision to the clinic, giving physicians a powerful tool to reduce uncertainty in a highly complex disease. It’s incredibly rewarding to see its positive impact on real-world patient care”.
